Biogen Idec/Elan Report Positive Two-Year Tysabri Follow-On Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Partners also announce that no new reports of progressive multifocal leukoencephalopathy have been associated with the multiple sclerosis therapy - at the international MS meeting in Prague.
You may also be interested in...
Bayer Schering Abandons Higher Dose Betaferon Following Disappointing Data
Head-to-head trial against Teva’s Copaxone in MS failed to show statistically significant superiority.
Bayer Schering Abandons Higher Dose Betaferon Following Disappointing Data
Head-to-head trial against Teva’s Copaxone in MS failed to show statistically significant superiority.
Genzyme/Bayer Report Positive Top-Line Phase II MS Data For Campath
Clinical hold on the Phase II trial was lifted “within the last six months” and dosing completed, Genzyme’s Enyedy says.